|[August 27, 2014]
Ryogen Awarded Two U.S. Patents Directed to Hepatitis C and Diabetes
SUFFERN, N.Y. --(Business Wire)--
LLC, an R&D company focusing on polynucleotide sequences implicated in
human diseases, was awarded two new patents, bringing the total number
of its issued U.S. Patents to 34.
U.S. Patent No. 8,795,959
titled "Isolated glucokinase genomic polynucleotide fragments from
chromosome 7" was issued August 5, 2014. This patent continues the theme
of a previously issued Ryogen patent, U.S. Patent No. 8,313,899.
The new patent claims a method of detection of specified sequences from
polynucleotide sequence which encodes a protein that has human
glucokinase activity. Glucokinase plays an important role in the
It serves as a glucose sensor of the insulin-producing pancreatic cells,
controls the conversion of glucose to glycogen in the liver, and
regulates hepatic glucose production. Mutations in the gene for this
enzyme are associated with different forms of Diabetes and Hypoglycemia.
U.S. Patent No.8,765,927
titled "Identification of isolated genomic nucleotide fragments from the
p15 region of chromosome 11 encoding human cluster of differentiation
antigen 81 and variants thereof" was issued on July 1, 2014. The patent
builds on other patents in Ryogen's portfolio directed to CD81, namely
U.S. Patent Nos. 8,039,602
It claims methods of identifying presence and variance of CD81 Genomic
DNA using short segments of non-coding DNA or RNA segments. The CD81
protein is a cell surface protein and has broad tissue distribution. It
plays a critical role in�Hepatitis
C�virus attachment and cell entry as well as being a factor in HIV
and influenza viruses pathogenesis. CD81 represents a potential
therapeutic target to ameliorate inflammatory neurological damage in MS.
The loss of CD81 is associated with differentiation and metastasis of
hepatocellular carcinoma. CD81 protein is expressed at high levels in
normal germinal center B cells and in subtypes of human lymphomas.
Valeria Poltorak, Executive Vice President of Ryogen, commented that
"the new patents are promising in defining novel therapeutic and
diagnostic targets for treatment of Hepatitis C and diabetes. The
company's patents are directed to polynucleotides implicated in various
cancers, diabetes and obesity, hepatitis C, atherosclerosis,
Alzheimer's, and other diseases."
In addition to its 34 issued patents, Ryogen has patent applications in
different stages of prosecution at the U.S. Patent Office. The complete
list of issued patents is available at the Patents
page of the Ryogen website. The whole IP portfolio is available for
licensing to research and business communities on very favorable terms.
About Ryogen LLC
LLC, a genetic R&D company focusing on nucleic acid sequences, implied
in human diseases, is located in Suffern, N.Y. Ryogen owns an
intellectual property portfolio of 34 patents and several patent
applications directed to potentially important applications in
biomedical research and, ultimately, diagnostics and drug development.
Ryogen was formed with the purpose of making its intellectual property
accessible to researchers via licensing of its patents. Ryogen is a
business unit in the idea incubator operated by IP
Holdings LLC, and Ryogen is managed by General
Patent Corporation (GPC). For further information, visit www.Ryogen.com.
About IP Holdings LLC
Holdings LLC, based in Suffern, N.Y., is an IP-centric merchant
banking organization that provides IP-related financial services, patent
brokerage services, and operates an idea
incubator that focuses on patent commercialization. IP Holdings is a
member of the GPC Group of Companies. For additional information, visit www.IP-Holdings.com.
About General Patent Corporation
Patent Corporation, headquartered in Suffern, N.Y., is a leading
intellectual property (IP) boutique focusing on patent licensing and patent
enforcement as well as IP
management and other IP
advisory services. For more information, visit www.GeneralPatent.com.
[ InfoTech Spotlight's Homepage ]